<DOC>
	<DOCNO>NCT00275015</DOCNO>
	<brief_summary>RATIONALE : Giving chemotherapy peripheral stem cell transplant stop growth cancer cell stop divide kill . Giving colony-stimulating factor , G-CSF , certain chemotherapy drug , help stem cell move bone marrow blood collect store . Chemotherapy radiation therapy give prepare bone marrow stem cell transplant . The stem cell return patient replace blood-forming cell destroy chemotherapy radiation therapy . PURPOSE : This phase II trial study well give cyclophosphamide together total-body irradiation work treat patient undergoing peripheral stem cell transplant chronic lymphocytic leukemia .</brief_summary>
	<brief_title>Cyclophosphamide Total Body Irradiation Treating Patients Who Are Undergoing Autologous Peripheral Stem Cell Transplant For Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine safety feasibility autologous peripheral blood stem cell transplantation patient chronic lymphocytic leukemia treat cyclophosphamide total-body irradiation . Secondary - Determine safety , feasibility , efficacy combination therapy comprise dexamethasone , carmustine , cytarabine , etoposide , melphalan ( Dexa-BEAM ) filgrastim ( G-CSF ) mobilization patient treat regimen . - Determine efficacy ex-vivo graft purge patient treated regimen . - Determine incidence complete clinical molecular remission patient treat regimen . - Determine progression-free survival patient treat regimen . OUTLINE : This multicenter , open-label , nonrandomized study . - Cytoreductive treatment : Patients undergo 2-4 course cytoreductive treatment , preferably follow fludarabine cyclophosphamide ( FC ) protocol . - Stem cell mobilization : Patients achieve complete remission ( CR ) partial remission ( PR ) stable blood count undergo stem cell mobilization comprise dexamethasone , carmustine , cytarabine , etoposide , melphalan ( Dexa-BEAM ) , filgrastim ( G-CSF ) . Patients adequate number mobilize cell undergo stem cell collection . Patients CR good PR proceed myeloablative therapy . - Myeloablative therapy : Patients undergo total-body irradiation day -4 receive cyclophosphamide IV day -4 -3 . - Autologous peripheral blood stem cell transplantation ( PBSCT ) : Patients undergo autologous PBSCT day 0 . After completion study , patient follow periodically . PROJECTED ACCRUAL : A total 150 patient accrue study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Patients chronic lymphocytic leukemia , meet 1 follow criterion : Binet stage B C disease Binet stage A disease high risk disease progression , define follow : Nonnodular marrow infiltration lymphocyte double time &lt; 12 month Thymidine kinase &gt; 7.0 U/L ÃŸ2microglobulin &gt; 3.5 mg/L Polymerase chain reactionamplifiable clonal CDRIII rearrangement IgV_H PATIENT CHARACTERISTICS : ECOG performance status 01 No concurrent disease result major organ dysfunction PRIOR CONCURRENT THERAPY : No prior combination therapy comprise melphalan , dexamethasone , carmustine , cytarabine , etoposide ( DEXABeam ) No 1 prior chemotherapy regimen No prior chemotherapy regimen longer 6 month duration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2007</verification_date>
	<keyword>stage 0 chronic lymphocytic leukemia</keyword>
	<keyword>stage I chronic lymphocytic leukemia</keyword>
	<keyword>stage II chronic lymphocytic leukemia</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
</DOC>